SciBase, Castle Biosciences enroll first patient in DETECT-AD study testing EIS to predict atopic dermatitis flares

Castle Biosciences

Castle Biosciences

CSTL

0.00
  • SciBase enrolled the first patient in DETECT-AD, a multicenter prospective study with Castle Biosciences in atopic dermatitis.
  • Electrical Impedance Spectroscopy will be evaluated for its ability to predict flare onset, aiming to support earlier, proactive treatment decisions.
  • No results have been presented; study findings are expected in the future.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SciBase Holding AB published the original content used to generate this news brief on June 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.